Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long‐Term Outcomes in a Prospective, Single‐Arm Trial

Documenti analoghi

• Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long‐Term Normalization of Systemic Sclerosis Molecular Signatures
  di: Nancy Wareing, et al.
  Pubblicazione: (2024)
• Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis: Current Evidence and Future Directions
  di: Cristiana Sieiro Santos
  Pubblicazione: (2025)
• Cytomegalovirus Infection After CD‐34 Selected Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis
  di: Brennan Collis, et al.
  Pubblicazione: (2025)
• Choreographing the Rhythms of Observation: Dynamics for Ranged Observer Bipartite-Unipartite SpatioTemporal (ROBUST) Networks
  di: Holmberg, Ted Edward
  Pubblicazione: (2024)
• The Number of CD34 Cells Employed in Autologous Hematopoietic Stem Cell Transplantation for Persons With Multiple Sclerosis Is Not Related to the Neurological Outcome of the Procedure
  di: Michelle Lavoignet‐Cisneros, et al.
  Pubblicazione: (2025)